Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity

Journal of Molecular and Cellular Cardiology

Volumn 33, Issue 6, 2001, Pages 1249-1261

  Shneyvays, V ^a   Mamedova, L ^a   Zinman, T ^a   Jacobson, K ^b   Shainberg, A ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adenosine receptors; Adriamycine; ATP; Calcium overloading; Cardioprotection; Doxorubicin; Image analysis; Lipid peroxidation

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CALCIUM ION; DOXORUBICIN; LACTATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CARDIOTOXICITY; CELL DAMAGE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME RELEASE; HEART MUSCLE CELL; HEART PROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

EID: 0034948867     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2001.1387     Document Type: Article

References (47)

1. Role of adenosine in the heart circulation
2. Receptors for purines and pyrimidines
3. Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges
4. Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart
5. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D
6. Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart
7. Adenosine improves recovery of postischemic myocardial function via an adenosine A1 receptor mechanism
8. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia
9. 3 adenosine receptor activation and its suppression by isoproterenol
10. Insights into adenosine A1 and A3 receptors function: Cardiotoxicity and cardioprotection
11. 3 receptor activation during hypoxia in isolated rat cardiac myocytes
12. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas
13. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity
14. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration
15. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response
16. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
17. 2+ handling
18. A calcium antagonist protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes
19. Inhibition of calcium accumulation by the sarcoplasmic reticulum: A putative mechanism for the cardiotoxicity of adriamycin
20. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2
21. Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist
22. Nondroplet ultrastructural demonstration of cytochrome oxidase activity with a polymerizing osmiophilic reagent, diaminobenzidine (DAB)
23. 2+ indicators with greatly improved fluorescence properties
24. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
25. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists
26. 2-Substitution of N6-benzyladenosine-5′-uronamides enhances selectivity for A3 adenosine receptors
27. 1 adenosine receptors
28. Modification by adenosine of the effect of adriamycin on myocardial cells in culture
29. Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine
30. Apoptosis induced by adenosine in human leukemia HL-60 cells
31. 3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders
32. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits
33. 2+ exchange of dog heart sarcolemmal vesicles
34. 3-adenosine receptors?
35. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
36. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation
37. Enhanced resistance of adriamycin-treated MCR-5 lung fibroblasts by increased intracellular glutathione peroxidase and extracellular antioxidants
38. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates
39. Adenosine acts as an endogenous activator of the cellular antioxidant defense system
40. Adenosine, antioxidant enzymes and cytoprotection
41. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: Suppression of cytochrome c oxidase II gene expression
42. Mitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissue
43. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios
44. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein. ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes
45. Selective activation of A3 adenosine receptors with N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits
46. A physiological role of the adenosine A3 receptor: Sustained cardioprotection